A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy

Dal Negro RW, Tognella S, Pradelli L

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details
Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. Journal of Asthma 2012; 49(8): 843-848

DOI
10.3109/02770903.2012.717659

Original Paper URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Antibodies, Monoclonal, Humanized; Asthma; Humans; Italy; Antibodies, Anti-Idiotypic

AccessionNumber
22012037001

Date bibliographic record published
14/02/2013